微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志

• 论文 • 上一篇    下一篇

高频热疗联合TP方案治疗中晚期非小细胞肺癌的疗效观察

刘阿海;李本全;李发强;王道军;靳桂红;   

  1. 河南焦作煤业集团中央医院肿瘤内科;
  • 收稿日期:2010-06-25 修回日期:2010-06-25 出版日期:2010-06-25 发布日期:2010-06-25

Effect of hyperthermotherapy combined with TP chemotherapy in treating advanced non-small cell lung cancer

LIU A-hai,LI Ben-quan,LI Fa-qiang,et al.   

  1. (Department of Oncology,Central Hospital of Coal Mining Group,Jiaozuo,Henan 454000,China
  • Received:2010-06-25 Revised:2010-06-25 Online:2010-06-25 Published:2010-06-25

赞

被引次数

10

摘要： 目的观察高频热疗联合TP方案治疗中晚期非小细胞肺癌(NSCLC)的近期疗效、生活质量、生存率及毒副反应。方法 60例NSCLC患者随机分为两组,观察组(30例)采用高频热疗联合紫杉醇+顺铂(TP方案)化疗,共4个周期。对照组(30例)仅采用TP方案静脉化疗,共4个周期。治疗结束后1个月评价和比较两组的近期疗效、1、2年生存率、生活质量及不良反应。结果两组在近期疗效、毒副反应发生率以及1、2年生存率的差异无统计学意义(P均>0.05),但观察组的生活质量较对照组明显提高(P<0.05)。结论高频热疗联合TP方案治疗非小细胞肺癌疗效确切,生活质量明显改善,毒副反应可耐受。

关键词: 非小细胞肺癌, 化疗, 高频热疗, 疗效

Abstract: Objective To evaluate the clinical efficacy,survival rate,life quality and side effects induced by hyperthermotherapy combined with TP chemotherapy in treating the patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty NSCLC patients were randomly divided into two groups.Group one(n=30)was treated with Paclitaxel plus cisplatin(TP)for four cycles,combined with hyperthermotherapy.Group two(n=30)was treated only with regular TP chemotherapy for four cycles.One month after treatment,the efficacy,life quality and side effects were compared between the two groups.Results The response rates in group one and group two were 46.7% and 36.7% respectively,and the difference between the two groups was not statistically significant(P>0.05).Between two groups,the difference of the change of KPS score before and after treatment was statistically significant(P<0.05).The toxic and side effects of the two groups had no significant difference.Conclusion The use of TP chemotherapy combined with hyperthermotherapy can increase efficacy and improve life quality of the patients with advanced NSCLC.

Key words: Non-small cell lung cancer(NSCLC), Chemotherapy, Hyperthermotherapy, Efficacy